Zenas BioPharma, Inc. Common Stock (ZBIO) - Net Assets
Based on the latest financial reports, Zenas BioPharma, Inc. Common Stock (ZBIO) has net assets worth $242.14 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($383.64 Million) and total liabilities ($141.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zenas BioPharma, Inc. Common Stock (ZBIO) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $242.14 Million |
| % of Total Assets | 63.12% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Zenas BioPharma, Inc. Common Stock - Net Assets Trend (2022–2025)
This chart illustrates how Zenas BioPharma, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore Zenas BioPharma, Inc. Common Stock (ZBIO) total assets for the complete picture of this company's asset base.
Annual Net Assets for Zenas BioPharma, Inc. Common Stock (2022–2025)
The table below shows the annual net assets of Zenas BioPharma, Inc. Common Stock from 2022 to 2025. For live valuation and market cap data, see Zenas BioPharma, Inc. Common Stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $242.14 Million | -22.50% |
| 2024-12-31 | $312.46 Million | +238.43% |
| 2023-12-31 | $-225.72 Million | -17.39% |
| 2022-12-31 | $-192.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zenas BioPharma, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 57184900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $-64.00K | -0.03% |
| Other Components | $1.01 Billion | 416.00% |
| Total Equity | $242.14 Million | 100.00% |
Zenas BioPharma, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Zenas BioPharma, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Blacksky Technology Inc
NYSE:BKSY
|
$1.21 Billion |
|
Beijing eGOVA
SHE:300075
|
$1.21 Billion |
|
Changjiang & Jinggong Steel Building Group Co Ltd
SHG:600496
|
$1.21 Billion |
|
Rolls-Royce Holdings PLC
LSE:RR
|
$1.21 Billion |
|
Aju IB Investment Co. Ltd
KQ:027360
|
$1.21 Billion |
|
Srisawad Power 1979 PCL
BK:SAWAD
|
$1.21 Billion |
|
Lions Gate Entertainment Corp
NYSE:LGF-B
|
$1.21 Billion |
|
Bega Cheese Ltd
AU:BGA
|
$1.21 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zenas BioPharma, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 312,458,000 to 242,144,000, a change of -70,314,000 (-22.5%).
- Net loss of 377,737,000 reduced equity.
- Share repurchases of 276,000 reduced equity.
- New share issuances of 148,573,000 increased equity.
- Other comprehensive income decreased equity by 258,000.
- Other factors increased equity by 159,384,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-377.74 Million | -156.0% |
| Share Repurchases | $276.00K | -0.11% |
| Share Issuances | $148.57 Million | +61.36% |
| Other Comprehensive Income | $-258.00K | -0.11% |
| Other Changes | $159.38 Million | +65.82% |
| Total Change | $- | -22.50% |
Book Value vs Market Value Analysis
This analysis compares Zenas BioPharma, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.58x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-5.02 | $19.36 | x |
| 2023-12-31 | $-5.89 | $19.36 | x |
| 2024-12-31 | $7.48 | $19.36 | x |
| 2025-12-31 | $5.41 | $19.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zenas BioPharma, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -156.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3777.37%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.58x
- Recent ROE (-156.00%) is below the historical average (-51.56%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-100.05 Million |
| 2023 | 0.00% | -74.25% | 0.73x | 0.00x | $-14.55 Million |
| 2024 | -50.24% | -3139.76% | 0.01x | 1.18x | $-188.23 Million |
| 2025 | -156.00% | -3777.37% | 0.03x | 1.58x | $-401.95 Million |
Industry Comparison
This section compares Zenas BioPharma, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zenas BioPharma, Inc. Common Stock (ZBIO) | $242.14 Million | 0.00% | 0.58x | $1.21 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, an… Read more